Finance

Lists
AORT:NYSE
Artivion Inc
USD 22,61
+1,34%
(+0,30) 1D
USD 22,61
0,00% (0,00)
After hours
Closed: 5 Okt., 16:00:06 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AORT...
Open
USD 22,21
High
USD 23,04
Low
USD 22,16
Mkt. cap
1,10 mjd
Avg. vol.
625,08 k
Volume
734,21 k
52-wk high
USD 48,25
52-wk low
USD 19,16
EPS
-USD 0,07
Beta
1,23
Shares outstanding
48,76 m
No. of employees
2 k
Open
USD 22,21
High
USD 23,04
Low
USD 22,16
Mkt. cap
1,10 mjd
Avg. vol.
625,08 k
Volume
734,21 k
52-wk high
USD 48,25
52-wk low
USD 19,16
EPS
-USD 0,07
Beta
1,23
Shares outstanding
48,76 m
No. of employees
2 k
News stories
From web sources and news partners
Profile
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. Wikipedia
About Artivion Inc
CEOJames Patrick Mackin
Employees1,8 k
Founded1984
HeadquartersKennesaw, Georgia, Verenigde State van Amerika
SectorMedical device
Analyst ratings
Based on 6 analysts giving stock ratings to AORT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AORT in the last 3 months.
Highest
Current USD 22,61
USD 45,00 (+99,03%)
Average
USD 41,87 (+85,18%)
Lowest
USD 38,00 (+68,07%)
Analyst
Recommendation
Action
Price target
Projected
Date
William Plovanic
Canaccord Genuity
Buy
Maintained
USD 40,00
+76,9%
08/18/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Maintained
USD 39,20
+73,4%
08/07/2026
Frank Takkinen
Lake Street
Buy
Reiterated
USD 45,00
+99%
08/07/2026
Suraj Kalia
Oppenheimer
Buy
Reiterated
USD 38,00
+68,1%
08/07/2026
Rick Wise
Stifel Nicolaus
Buy
Reiterated
USD 45,00
+99%
08/07/2026
Michael Matson
Needham
Buy
Reiterated
USD 44,00
+94,6%
08/07/2026
Daniel Stauder
Citizens JMP
Buy
Maintained
USD 48,00
+112,3%
05/08/2026
Eric Martinuzzi
Lake Street
Buy
Reiterated
USD 55,00
+143,3%
04/08/2026
Last report
06 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 0,13 / USD 0,10
+34,48%beat
Revenue / Est. (USD)
125,76 m / 120,01 m
+4,79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
113,39 m
115,99 m
116,34 m
125,76 m
Cost of goods sold
38,99 m
42,85 m
40,89 m
45,24 m
Cost of revenue
38,99 m
42,85 m
40,89 m
45,24 m
Research and development expenses
8,08 m
9,12 m
8,84 m
9,06 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
54,68 m
54,64 m
60,58 m
60,13 m
Operating expense
62,76 m
63,76 m
69,42 m
69,18 m
Total operating expenses
101,75 m
106,61 m
110,31 m
114,42 m
Operating income
11,64 m
9,38 m
6,03 m
11,34 m
Other non operating income
499,00 k
1,18 m
514,00 k
-49,00 k
EBT including unusual items
7,06 m
6,54 m
339,00 k
-11,70 m
EBT excluding unusual items
6,16 m
5,15 m
579,00 k
3,70 m
Income tax expense
554,00 k
4,11 m
-1,08 m
1,81 m
Effective tax rate
7,85%
62,89%
-317,99%
-15,48%
Other operating expenses
-
-
-
-
Net income
6,50 m
2,43 m
1,42 m
-13,51 m
Net profit margin
5,73%
2,09%
1,22%
-10,74%
Earnings per share
0,16
0,17
0,08
0,13
Interest and investment income
240,00 k
311,00 k
205,00 k
367,00 k
Interest expense
-6,12 m
-5,62 m
-5,37 m
-7,25 m
Net interest expenses
-5,88 m
-5,31 m
-5,16 m
-6,89 m
Depreciation and amortization charges
-
-
-
-
EBITDA
17,35 m
15,14 m
12,37 m
18,08 m
Gain or loss from assets sale
-3,50 m
-3,50 m
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme